PDCD1 and cancer: Therapeutic antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or the axis of programmed cell death protein 1 (PD-1) and its corresponding ligand PD-L1 have shown compelling results in several different cancer types, including metastasized melanoma and lung cancer [36, 203].